The Dispute

Joy Behar, co-host of The View, went full alarm-bell on May 19, according to MRC NewsBusters. Her exact words: "Once Trump puts his name on prescriptions, we're all going to die."

She followed it up by rattling off Trump's business failures — the Shuttle, the Vodka, Trump University, the bankrupt casinos. As if the FDA approval process for a generic metformin tablet depends on the branding history of a Manhattan hotel.

Oz Hits Back

On May 20, Dr. Mehmet Oz — the 17th Administrator of the Centers for Medicare & Medicaid Services — responded on X with surgical sarcasm.

"Unfortunately, we still have no medications for Trump derangement syndrome on TrumpRx.gov, but we're working on it," Oz posted, according to Fox News and WFMD.

Behar's segment offered no substantive criticism of the drug-pricing mechanism, the pharmacy benefit manager system, or the actual cost structure. Just cultural commentary and Trump jokes.

Her Own Co-Host Disagreed

Alyssa Farah Griffin, also a View co-host, pushed back directly. According to WFMD, Griffin said: "The drugs don't actually have his name. A medication I had to take for IVF is a tenth of the price on TrumpRx."

Griffin added: "You're not gonna convince me that just because Trump's involved, we should be like, 'Screw it. Don't bring down prescription drug costs.'"

Sunny Hostin sided with Behar and questioned Trump's motives. But motives don't change the price on the receipt.

The Actual Policy Update

Our previous coverage broke down the May 18 TrumpRx expansion — 600-plus generics added, Amazon Pharmacy, GoodRx, and Mark Cuban's Cost Plus Drugs brought on as partners.

What's new since then is the political blowback and who's defending it.

Cuban — a billionaire who has been a consistent Trump critic — stood at the White House for that announcement. According to PJ Media, his presence should have slowed the usual reflexive criticism. It didn't.

The Associated Press reported, as cited by PJ Media and ZeroHedge, that the TrumpRx expansion is the administration's direct response to Democratic criticism that the original site was "performative" and that brand-name drugs on it were already cheaper with insurance elsewhere. The generic expansion addresses that criticism head-on.

What Mainstream Coverage Is Getting Wrong

Left-leaning coverage is framing this story entirely through the Behar prism — cultural outrage, Trump branding, skepticism of motive.

Right-leaning coverage is framing it as a clean win and dunking on Behar.

Neither approach addresses the harder questions.

TrumpRx does NOT replace insurance. It does NOT fix pharmacy benefit managers — the actual middlemen inflating drug prices for decades. It does NOT address the fact that, as the AP noted, Republican-led Medicaid cuts and the expiration of enhanced ACA subsidies are hitting Americans' premiums at the same moment the administration is rolling out a drug discount tool.

Giving cash-paying customers a price-comparison site is genuinely useful. Pretending it solves the American healthcare cost crisis is another thing entirely. Both assessments can hold true simultaneously.

For Regular People

If you're uninsured, on a high-deductible plan, or just paying cash at the pharmacy counter, TrumpRx.gov is worth checking. That's a fact regardless of who you voted for.

Dr. Oz won the Twitter exchange. The harder win — actually restructuring drug pricing in a way that doesn't crumble the moment a new administration takes over — hasn't happened yet for anyone, Republican or Democrat.